Assignee
BIOTIE THERAPIES CORP
FI·10 granted patents·2 pending applications·31 citations·filing 1998–2017
Top patents by PatentIndex Score
12 records- 0179US6624202B2Inhibitors of copper-containing amine oxidasesBIOTIE THERAPIES CORP·Filed 2001·Granted Sep 23, 2003·14 cites·15 claims
- 0269US6982286B2Carbocyclic hydrazino inhibitors of copper-containing amine oxidasesBIOTIE THERAPIES CORP·Filed 2001·Granted Jan 3, 2006·6 cites·11 claims
- 0368US7897149B2Fully human anti-VAP-1 monoclonal antibodiesBIOTIE THERAPIES CORP·Filed 2008·Granted Mar 1, 2011·2 cites·17 claims
- 0467US10576148B2Use of VAP-1 inhibitors for treating fibrotic conditionsBIOTIE THERAPIES CORP·Filed 2017·Granted Mar 3, 2020·1 cites·17 claims
- 0567US9815795B2Pyridazinone and pyridone compoundsBIOTIE THERAPIES CORP·Filed 2016·Granted Nov 14, 2017·1 cites·15 claims
- 0665US7399626B2Glucuronyl C5-epimerase, DNA encoding the same and uses thereofBIOTIE THERAPIES CORP·Filed 2005·Granted Jul 15, 2008·1 cites·24 claims
- 0751US2010261253A1Glucuronyl C5-Epimerase, DNA encoding the same and uses thereofBIOTIE THERAPIES CORP·Filed 2008·Application pending·0 cites
- 0850US10479771B2Pyridazinone and pyridone compoundsBIOTIE THERAPIES CORP·Filed 2017·Granted Nov 19, 2019·0 cites·5 claims
- 0946US6764844B1DNA sequence encoding a novel glucuronyl C5-epimeraseBIOTIE THERAPIES CORP·Filed 1998·Granted Jul 20, 2004·5 cites·50 claims
- 1040US7499847B2Crystalline VAP-1 and uses thereofBIOTIE THERAPIES CORP·Filed 2004·Granted Mar 3, 2009·0 cites·6 claims
- 1132US6492344B1Syndecan enhancer element and syndecan stimulation of cellular differentiationBIOTIE THERAPIES CORP·Filed 1999·Granted Dec 10, 2002·1 cites·11 claims
- 1232US2009286713A9Collagen Receptor I-Domain Binding ModulatorsBIOTIE THERAPIES CORP·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIOTIE THERAPIES CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →